PRKCA and colorectal carcinoma: However, despite the findings suggesting that PKCα is a potential drug target candidate for inhibiting the constitutively activated Wnt/β-catenin pathway in CRC, it is not known whether increasing PKCα activity is beneficial for fighting CRC.